Shares of adhesives maker H.B. Fuller sink on warning of 'slower than anticipated' demand
Shares of H.B. Fuller Co. (FUL) fell after hours on Wednesday after the adhesives maker said "generally slower industrial demand" weighed on its third-quarter results and full-year forecast. The company -- whose adhesives and sealants are used in food containers, medical products, shoes, automobiles and an array of other products -- said it expected full-year adjusted earnings per share to be $3.80 to $3.90, compared with a forecast in June for $3.80 to $4.20. It also said it expected revenue of $3.5 billion to $3.55 billion, on "lower volume expectations due to customer destocking actions and slower than anticipated underlying demand conditions." Shares fell 1% after hours. The company reported net income of $37.6 million, or 67 cents a share, compared with $46.5 million, or 84 cents a share, in the same quarter last year. Revenue fell to $900.6 million from $941.2 million in the prior-year quarter. Adjusted earnings per share were $1.06. Analysts polled by FactSet expected adjusted earnings of $1.14 a share and $954 million in sales.
-Bill Peters
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-27-23 1638ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks